Skip to main content

Table 2 Results

From: Intramuscular autologous blood therapy - a systematic review of controlled trials

Authors

Indication

Sample size

Design

Duration of treatment

Frequency and dosage

Outcome: doctor’s statement p = … in favor to patient’s statement

Comment

Abdallah et al. [14]

Chronic autoreactive urticaria

30 ASST+ (15 AWB, 15 AS)

RCT: AWB vs. AS, not blinded

8 weeks

1x/w; AWB: 1st injection 2.5 ml, following 5 ml;

AS: 2 ml every time

AWB: p < 0.01 (weeks 8 + 12)

AS: p < 0.01 (weeks 8 + 12)

No statistical difference between treatments

 

Hensler, Gündling et al. [15]

Treatment of Common Cold

114 (58 AWB, 56 Placebo)

RCT: AWB vs. Placebo

double-blinded

1 week

3x/w 2 ml

No statistical difference

 

Jobst, Altiner et al. [2]

prevention of recurring respiratory tract infections

75 (38 AWB, 37 Engystol®)

RCT: AWB vs. Engystol®, not blinded

5 weeks

2x/w 3 ml

No statistical difference between AWB and Engystol®

 

Kocatürk et al. [16]

Urticaria

88 (ASST+ 59: 20 AWB, 20 AS, 19 Placebo; ASST- 29: 9 AWB, 10 AS, 10 Placebo)

RCT: AWB vs. AS vs. Placebo, single-blinded

10 weeks

1x/w; 1st injection 2.5 ml, following 5 ml

No statistical difference

 

Min et al. [17]

Chronic Urticaria

157 (52 AWB, TCM (Chinese Herbs) + Western Medicine,

53 Western Medicine,

52 TCM)

Controlled trial: AWB + TCM + Western Medicine vs. TCM vs. Western Medicine, not randomized, not blinded

24 days

Every 3 days (total of 8 injections)

5 ml AWB + 1 ml lidocaine + 4 ml H2O, each side 5 ml

Treatment group (AWB + TCM + Western Medicine) more effective than the other groups (p < 0.05)

 

Pittler, Ernst et al. [3]

Atopic Dermatitis

30 (15 AWB, 15 Placebo)

RCT: AWB vs. Placebo, double-blinded

5 weeks

1x/w; 1–2 – 3 – 2 – 1 ml

SASSAD score: week 5 P = 0.001

week 9 P < 0.001

patient’s statement: no statistical difference

 

Schirmer, Fritz, Jäckel [18]

Spondylitis ankylosans

100 (51 AWB + Formica, 49 Placebo)

+ training scheme (both groups)

RCT: AWB + Formica vs. Placebo

double-blinded

4 weeks

2x/w 1 ml AWB + 1 ml Formica rufa 6x

No statistical difference

Trial effected in rehabilitation facility

Staubach, Onnen et al. [19]

Chronic Urticaria

48 (29 ASST+: 13 AWB, 16 Placebo, 19 ASST-: 10 AWB, 9 Placebo)

RCT: AWB vs. Placebo, single-blinded

8 weeks

1x/w; 1st injection 2.5 ml, following 5 ml

ASST+ patients:

AWB UAS −41%,

p < 0.05, wheals duration + size −46%/−48%, p < 0.05, erythema −56%, p < 0.05, DLQI week8 + 70%, p < 0.005, week12 + 66%, p < 0.05, antihistamines −52%, p < 0.05; Placebo UAS −18%;

ASST- patients:

AWB UAS −21%,

Placebo UAS −11%

Â